Medicare Enrolled
Dr. Zahra Afshari, M.D.
Neurology · Glenview, IL
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Afshari from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Afshari?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Afshari
Dr. Zahra Afshari is a neurology specialist in Glenview, IL, with 19 years of NPI registration. Based on federal Medicare data, Dr. Afshari performed 1,960 Medicare services across 529 unique beneficiaries.
Between the years covered by Open Payments, Dr. Afshari received a total of $19,371 from 72 pharmaceutical and/or device companies across 920 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Afshari is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 15% volume in IL
$19,371 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,960
Medicare services
Top 15% in IL for neurology
529
Unique beneficiaries
$62
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~103 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
1,157 | $27 | $100 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
420 | $146 | $361 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
91 | $75 | $100 |
| Annual depression screening | 85 | $19 | $31 |
| Neurobehavioral status exam, first hour A clinical assessment of neurobehavioral status lasting one hour. This evaluation examines mental and behavioral functions. |
59 | $78 | $285 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
54 | $106 | $150 |
| New patient office visit, complex (60-74 min) | 47 | $186 | $554 |
| Telephone medical discussion, 5-10 minutes A phone conversation with a physician lasting between 5 and 10 minutes to discuss medical matters. |
47 | $47 | $75 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$19,371
Total received (2018-2024)
Avg $2,767/year across 7 years
Top 15% in IL for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
72
Companies
920
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$18,387 (94.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$984 (5.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,606
2023
$4,205
2022
$3,380
2021
$2,547
2020
$2,173
2019
$2,142
2018
$1,318
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Neurocrine Biosciences, Inc.
$505
ABBVIE INC.
$485
PFIZER INC.
$308
Amneal Pharmaceuticals LLC
$286
UCB, Inc.
$261
ACADIA Pharmaceuticals Inc
$243
Lilly USA, LLC
$179
Genentech USA, Inc.
$155
Eisai Inc.
$152
ARGENX US, INC.
$144
Acorda Therapeutics, Inc
$139
Sumitomo Pharma America, Inc.
$97
Kyowa Kirin, Inc.
$76
Novo Nordisk Inc
$75
Lundbeck LLC
$74
MITSUBISHI TANABE PHARMA AMERICA, INC.
$72
MDD US Operations, LLC
$66
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$57
Corium, LLC
$53
Supernus Pharmaceuticals, Inc.
$29
Otsuka America Pharmaceutical, Inc.
$26
Biogen, Inc.
$25
BANNER LIFE SCIENCES, LLC
$24
Merz Pharmaceuticals, LLC
$21
Xeris Pharmaceuticals, Inc.
$19
BioMarin Pharmaceutical Inc.
$18
IDORSIA PHARMACEUTICALS US INC
$16
Top 3 companies account for 36.0% of 2024 payments
All-time payments by company (2018-2024) ›
UCB, Inc.
$1,805
Supernus Pharmaceuticals, Inc.
$1,410
Teva Pharmaceuticals USA, Inc.
$1,231
Neurocrine Biosciences, Inc.
$1,227
AbbVie Inc.
$958
Lundbeck LLC
$848
ABBVIE INC.
$786
Biogen, Inc.
$783
ACADIA Pharmaceuticals Inc
$706
Lilly USA, LLC
$629
Acorda Therapeutics, Inc
$563
Amneal Pharmaceuticals LLC
$562
PFIZER INC.
$501
SK Life Science, Inc.
$454
Takeda Pharmaceuticals U.S.A., Inc.
$434
Alnylam Pharmaceuticals Inc.
$421
MDD US Operations, LLC
$387
Eisai Inc.
$359
Biohaven Pharmaceutical Holding Company Ltd.
$339
Otsuka America Pharmaceutical, Inc.
$335
Genentech USA, Inc.
$330
Amgen Inc.
$293
Novo Nordisk Inc
$268
IDORSIA PHARMACEUTICALS US INC
$257
AbbVie, Inc.
$242
MITSUBISHI TANABE PHARMA AMERICA, INC.
$202
Allergan, Inc.
$159
Biohaven Pharmaceuticals, Inc.
$154
JAZZ PHARMACEUTICALS INC.
$146
Upsher-Smith Laboratories LLC
$146
Avanir Pharmaceuticals, Inc.
$144
ARGENX US, INC.
$144
EISAI INC.
$134
US WorldMeds, LLC
$111
EMD Serono, Inc.
$109
Kyowa Kirin, Inc.
$103
Sumitomo Pharma America, Inc.
$97
Promius Pharma LLC
$94
UPSHER-SMITH LABORATORIES LLC
$91
Alfasigma USA, Inc.
$75
Assertio Therapeutics, Inc.
$67
BANNER LIFE SCIENCES, LLC
$67
CATALYST PHARMACEUTICALS, INC.
$66
Xeris Pharmaceuticals, Inc.
$63
Janssen Pharmaceuticals, Inc
$58
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$57
Vertical Pharmaceuticals, LLC
$55
GlaxoSmithKline, LLC.
$55
Novartis Pharmaceuticals Corporation
$54
Cala Health, Inc.
$54
Avion Pharmaceuticals
$53
Corium, LLC
$53
Exeltis, USA Inc.
$50
Sunovion Pharmaceuticals Inc.
$48
Alexion Pharmaceuticals, Inc.
$47
Currax Pharmaceuticals LLC
$45
Mallinckrodt Hospital Products Inc.
$44
Amarin Pharma Inc.
$41
IMPEL PHARMACEUTICALS INC.
$40
BioMarin Pharmaceutical Inc.
$33
TerSera Therapeutics LLC
$31
Abbott Laboratories
$30
ANI Pharmaceuticals, Inc.
$30
Akcea Therapeutics, Inc.
$27
Neurelis, Inc.
$24
Bausch Health US, LLC
$22
ITI, Inc.
$22
Greenwich Biosciences, Inc.
$21
Banner Life Sciences, LLC
$21
Merz Pharmaceuticals, LLC
$21
TG THERAPEUTICS, INC.
$17
Allergan Inc.
$17
Top 3 companies account for 22.9% of all-time payments
Associated products mentioned in payments ›
ABILIFY MAINTENA · ACTHAR · ADUHELM · AIMOVIG · AJOVY · AMVUTTRA · AMYVID · APOKYN · APTIOM · AUSTEDO · AVONEX · Aimovig · Apokyn · Austedo XR · Azstarys · BAFIERTAM · BENLYSTA · BOTOX · BOTOX THERAPEUTIC · BRINTELLIX · BRIUMVI · Belviq · Briviact · CALA KIQ · CALA TRIO · CAMBIA · CAPLYTA · CREXONT · Cenobamate · DIVIGEL · DUOPA · Dhivy · Duopa · EMGALITY · EPIDIOLEX · Enspryng · Epidiolex · FIRDAPSE · Fycompa · GAMMAGARD · GAMMAGARD LIQUID · GOCOVRI · GVOKE PFS · Gocovri · INBRIJA · INFINITY · INGREZZA · KEVEYIS · KISUNLA · LEQEMBI · Leqembi · MIGRANAL · MYOBLOC · Mavenclad · NORTHERA · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Nayzilam · Neupro · Nourianz · OCREVUS · ONGENTYS · ONPATTRO · ONZETRA XSAIL · ONZETRA Xsail · OSMOLEX ER · OXTELLAR XR · Ocrevus · Ongentys · PAXLOVID · PRIALT · PURIFIED CORTROPHIN GEL · Ponvory · QELBREE · QUDEXY XR TOPIRAMATE EXTENDED RELEASE CAPSULES · QULIPTA · QUVIVIQ · Qelbree · RADICAVA · REXULTI · REYVOW · RYTARY · Rebif · Rystiggo · SOLIRIS · SPINRAZA · SUNOSI · Saxenda · Soliris · TECFIDERA · TEGSEDI · TOSYMRA · TOSYMRA SUMATRIPTAN NASAL SPRAY · TRINTELLIX · TROKENDI XR · TYSABRI · Trudhesa · UBRELVY · VALTOCO · VIMIZIM · VRAYLAR · VUMERITY · VYEPTI · VYVANSE · VYVGART HYTRULO · Vascepa · Vimizim · Vimpat · Wegovy · XCOPRI · Xadago · Xeomin · ZEMBRACE SYMTOUCH · ZEMBRACE SYMTOUCH SUMATRIPTAN INJECTION · Zelnorm · Zembrace
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (95%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Neurologists within 10 mi
596
Per 100K population
11.5
County median income
$81,797
Nearest hospital
CHICAGO BEHAVIORAL HOSPITAL
3.9 mi
3.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Afshari is a clinical cardiology specialist, with above-average Medicare volume (top 15% in IL), with low-engagement industry engagement in the top 15% of IL peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Afshari experienced with prolonged office e/m service, first 15 minutes?
Based on Medicare claims data, Dr. Afshari performed 1,157 prolonged office e/m service, first 15 minutes services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Afshari receive payments from pharmaceutical companies?
Yes. Dr. Afshari received a total of $19,371 from 72 companies across 920 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Afshari's costs compare to other neurologists in Glenview?
Dr. Afshari's average Medicare payment per service is $62. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Afshari) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Neurology
Common procedures, typical costs, and what industry payments mean in neurology.
Same specialty & city
Neurologists in Glenview
Browse neurologists in Glenview ranked by procedure volume and transparency data.
Highest volume
Top Neurologists in IL
Neurologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neurologists in IL
Which IL neurologists receive the most from drug and device companies.
By company
UCB, Inc. Payments to Doctors
See all physicians who received payments from UCB, Inc.
By company
Supernus Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Supernus Pharmaceuticals, Inc.
By company
Teva Pharmaceuticals USA, Inc. Payments to Doctors
See all physicians who received payments from Teva Pharmaceuticals USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology